A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
The purpose of this study is to describe the demographic and clinical profiles of patients with early-stage HER2+ breast cancer treated with neratinib as an extended adjuvant therapy as part of the Early Access Program (EAP) in Europe.
Breast Cancer|Adjuvant Therapy|HER2-positive Breast Cancer
Description of age, Age will be assessed in years = neratinib initiation date - date of birth, At baseline|Description of Gender, Gender will be described in percentage of Male and Female among patients, At baseline|Description of BMI, BMI will be assessed in kg/m2, At baseline|Menopausal status, Menopausal status will be described in percentage of Premenopausal, Perimenopausal, Postmenopausal, Surgical/other reason for amenorrhea, At baseline|Comorbidities, Comorbidities will be described in number and percentage of patients with at least one relevant comorbidity, At baseline|HER2 overexpression/amplification testing, HER2 overexpression/amplification testing will be assessed by Immunohistochemistry (IHC), Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), At initial diagnosis|Hormone receptor status, Hormone receptor status will be described in percentage of patients with Estrogen receptor (ER) positive, Progesterone receptor (PR) positive, ER and PR negative, At initial diagnosis|Primary tumor location, Primary tumor location will be described in percentage of patients with Left Breast cancer, Right Breast cancer, At initial diagnosis|Primary tumor histology, Primary tumor histology will be described in percentage of patients with Infiltrating ductal carcinoma, Infiltrating lobular carcinoma, Invasive carcinoma, Tubular, Other, At initial diagnosis|Histological grade, Histological grade will be described in percentage of patients with G1 Well differentiated, G2 Moderately differentiated, G3 Poorly differentiated, G4 Undifferentiated, At initial diagnosis|Pathologic stage (AJCC classification) of Breast Cancer, Pathologic stage (AJCC classification) of Breast Cancer will be described in percentage of patients with stages 1, 2A, 2B, 3A, 3B, 3C, At initial diagnosis
The purpose of this study is to describe the demographic and clinical profiles of patients with early-stage HER2+ breast cancer treated with neratinib as an extended adjuvant therapy as part of the Early Access Program (EAP) in Europe.